Immix Biopharma (IMMX) Research & Development (2021 - 2026)
Immix Biopharma (IMMX) posted Research & Development of $6.0 million for Q1 2026, up 4.43% sequentially from $5.7 million in Q4 2025, and up 202.8% YoY from $2.0 million in Q1 2025.
Immix Biopharma (IMMX) Research & Development (2021 - 2026) Analysis & Trends
Immix Biopharma has reported Research & Development for 6 years, with the latest figure at $6.0 million in Q1 2026.
- Quarterly Research & Development rose 202.8% year-over-year to $6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.3 million (up 102.25% YoY) and the FY2025 annual result came in at $16.3 million, up 43.97% from the prior year.
- Research & Development improved to $6.0 million in Q1 2026 per IMMX's latest filing, from $5.7 million in the prior quarter.
- Over five years, Research & Development peaked at $6.0 million in Q1 2026 and troughed at $607751.0 in Q2 2022.
- A 5-year average of $2.7 million and a median of $2.2 million in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2024: Research & Development jumped 24397.17% in 2022, then tumbled 55.68% in 2024.
- Over 5 years, Research & Development stood at $2.3 million in 2022, then jumped by 37.05% to $3.1 million in 2023, then tumbled by 55.68% to $1.4 million in 2024, then soared by 316.7% to $5.7 million in 2025, then gained by 4.43% to $6.0 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $6.0 million, $5.7 million, and $4.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Immix Biopharma | 784.75 Mn | 784.75 Mn | - | 5.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.33 Mn |
| Mar 31, 2026 | 5.98 Mn |
| Dec 31, 2025 | 5.73 Mn |
| Sep 30, 2025 | 4.58 Mn |
| Jun 30, 2025 | 3.97 Mn |
| Mar 31, 2025 | 1.98 Mn |
| Dec 31, 2024 | 1.37 Mn |
| Sep 30, 2024 | 4.45 Mn |
| Jun 30, 2024 | 2.22 Mn |
| Mar 31, 2024 | 3.25 Mn |
| Dec 31, 2023 | 3.10 Mn |
| Sep 30, 2023 | 2.11 Mn |
| Jun 30, 2023 | 2.21 Mn |
| Mar 31, 2023 | 1.32 Mn |
| Dec 31, 2022 | 2.26 Mn |
| Sep 30, 2022 | 695,937.00 |
| Jun 30, 2022 | 607,751.00 |
| Mar 31, 2022 | 629,531.00 |
| Dec 31, 2021 | 9,236.00 |
| Sep 30, 2021 | 29,690.00 |